Ellen Donnelly
Director Ejecutivo en ABLIVA AB .
Cargos activos de Ellen Donnelly
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| ALZECURE PHARMA AB | Director/Miembro de la Junta | 01/01/2018 | - |
| Independent Dir/Board Member | 01/01/2018 | - | |
| MODUS THERAPEUTICS HOLDING AB | Director/Miembro de la Junta | 01/01/2020 | - |
| Independent Dir/Board Member | 01/01/2020 | - | |
| Director Ejecutivo | - | 01/01/2020 | |
| ABLIVA AB | Director Ejecutivo | 03/02/2021 | - |
Modus Therapeutics AB
 Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | Director/Miembro de la Junta | 01/01/2019 | - |
| Director Ejecutivo | 01/01/2016 | 01/01/2019 |
Historial de carrera de Ellen Donnelly
Antiguos cargos conocidos de Ellen Donnelly.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
Juvenescence Ltd.
 Juvenescence Ltd. Financial ConglomeratesFinance Juvenescence Ltd. engages in operation as an investment holding company which develops therapeutic products for human ageing and longevity. It provides drug development, new company creation, academic licensing, and biotech investment. The company was founded by James Mellon, Gregory H. Bailey, Declan Dooganin, Alexander Pickett, and Anthony Chow in October 2016 and is headquartered in Liverpool, the United Kingdom. | Corporate Officer/Principal | - | - |
Formación de Ellen Donnelly.
| Yale School of Medicine | Doctorate Degree |
Estadísticas
Internacional
| Suecia | 5 |
| Reino Unido | 2 |
| Estados Unidos | 2 |
Operativa
| Director/Board Member | 3 |
| Chief Executive Officer | 3 |
| Independent Dir/Board Member | 2 |
Sectorial
| Health Technology | 5 |
| Finance | 2 |
| Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 3 |
|---|---|
| ALZECURE PHARMA AB | Health Technology |
| MODUS THERAPEUTICS HOLDING AB | Health Technology |
| ABLIVA AB | Health Technology |
| Empresas privadas | 2 |
|---|---|
Modus Therapeutics AB
Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | Health Technology |
Juvenescence Ltd.
Juvenescence Ltd. Financial ConglomeratesFinance Juvenescence Ltd. engages in operation as an investment holding company which develops therapeutic products for human ageing and longevity. It provides drug development, new company creation, academic licensing, and biotech investment. The company was founded by James Mellon, Gregory H. Bailey, Declan Dooganin, Alexander Pickett, and Anthony Chow in October 2016 and is headquartered in Liverpool, the United Kingdom. | Finance |
- Bolsa de valores
- Insiders
- Ellen Donnelly
- Experiencia